Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totalling 815,238 shares, a decline of 26.0% from the August 31st total of 1,101,312 shares. Approximately 2.9% of the company’s stock are sold short. Based on an average daily trading volume, of 173,425 shares, the days-to-cover ratio is presently 4.7 days.

Aevi Genomic Medicine (GNMX) opened at 1.28 on Tuesday. The stock’s market cap is $47.50 million. The firm’s 50 day moving average price is $1.29 and its 200 day moving average price is $1.42. Aevi Genomic Medicine has a one year low of $0.98 and a one year high of $17.75.

A number of hedge funds and other institutional investors have recently bought and sold shares of GNMX. TIAA CREF Investment Management LLC grew its holdings in Aevi Genomic Medicine by 16.7% during the 1st quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 13,966 shares in the last quarter. Teachers Advisors LLC acquired a new stake in shares of Aevi Genomic Medicine during the 4th quarter valued at approximately $204,000. Birchview Capital LP raised its position in shares of Aevi Genomic Medicine by 88.2% during the 2nd quarter. Birchview Capital LP now owns 128,000 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 60,000 shares in the last quarter. Northern Capital Management LLC raised its position in shares of Aevi Genomic Medicine by 317.9% during the 2nd quarter. Northern Capital Management LLC now owns 106,050 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 80,675 shares in the last quarter. Finally, LMR Partners LLP acquired a new stake in shares of Aevi Genomic Medicine during the 2nd quarter valued at approximately $149,000. Hedge funds and other institutional investors own 20.82% of the company’s stock.

Several research analysts have recently issued reports on GNMX shares. Needham & Company LLC lowered their target price on shares of Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, August 16th. Jefferies Group LLC reiterated a “hold” rating and set a $1.50 price target on shares of Aevi Genomic Medicine in a research note on Thursday, September 28th.

TRADEMARK VIOLATION NOTICE: “Short Interest in Aevi Genomic Medicine, Inc. (GNMX) Declines By 26.0%” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/03/short-interest-in-aevi-genomic-medicine-inc-gnmx-declines-by-26-0.html.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease.

Receive News & Stock Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related stocks with our FREE daily email newsletter.